NeuroDerm

NeuroDerm is a developer of therapies for the central nervous system, currently focusing on developing a series of drug-device combinations for the treatment of Parkinson's disease. The company’s lead product, ND0612, has initiated Phase III clinical trials in the United States and the European Union. Given the importance of controlling blood levodopa (L-dopa) levels in the treatment of Parkinson’s disease, ND0612 is expected to be used in advanced-stage Parkinson’s patients as well as those for whom oral levodopa no longer effectively controls motor complications.